Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $2.56 Million - $3.26 Million
-5,900 Reduced 15.53%
32,100 $17.4 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $13.5 Million - $17.2 Million
38,000 New
38,000 $16.3 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Melqart Asset Management (Uk) LTD Portfolio

Follow Melqart Asset Management (Uk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Melqart Asset Management (Uk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Melqart Asset Management (Uk) LTD with notifications on news.